Alex Hanly – CEO – Lithium Universe (ASX:LU7) objective is to construct a Lithium Project in Québec with utmost speed, and to assist Canada facilitate the transition towards cleaner energy.
Copyright 2023 – Finance News Network
Source: Finance News Network
10 Jul 2023 - INOVIQ Limited (ASX:IIQ) CEO Dr Leearne Hinch discusses recent news, including excellent sensitivity and specificity results for the company's SubB2M breast cancer test.
Read More01 Aug 2023 - QX Resources Limited (ASX:QXR) Managing Director Steve Promnitz discusses progress with the company's lithium project in California, including permitting, access to water and timeline ahead.
Read More27 Aug 2021 - LBT Innovations Limited (ASX:LBT) CEO and Managing Director Brent Barnes provides an update on sales and distribution for the company's Automated Plate Assessment System (APAS), which is used to read culture plates in laboratories.
Read More18 Dec 2019 - Oventus Medical Limited (ASX:OVN) Managing Director and CEO, Dr Chris Hart talks about the company's North American sales process via its lab in lab model and how this improves patient outcomes.
Read More03 Jun 2020 - Cyclopharm (ASX:CYC) Managing Director and CEO James McBrayer provides an update on US FDA progress with Technegas, approval in Russia and potential use of Technegas in the diagnosis and management of COVID-19.
Read More21 Jun 2022 - BluGlass Limited (ASX:BLG) President Jim Haden discusses shipping an alpha product to a customer, and the development roadmap for the company.
Read More05 May 2022 - Elementos Limited (ASX:ELT) Managing Director Joe David discusses factors behind the recent increase in the tin price and outlines Elementos' key project in Oropesa, Spain.
Read More11 Aug 2020 - Regeneus (ASX:RGS) CEO, Leo Lee talks about its collaboration with Kyocera of Japan to market Progenza its cell therapy treatment for anti-inflammatory treatment and repair of damaged or diseased tissue.
Read More16 Aug 2023 - Steven Yatomi Clarke - CEO and Managing Director - Prescient Therapeutics (ASX:PTX) is a clinical-stage biotech company developing personalised medicine approaches to cancer, including targeted and cellular therapies.
Read More28 Aug 2019 - Noxopharm Limited (ASX:NOX) CEO Dr Greg van Wyk discusses the company's anti-prostate cancer drug Veyonda, its efficacy in prostate cancer treatment, the drug’s upside and the company’s strategy for growth.
Read More
